<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03325790</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-1005-251</org_study_id>
    <nct_id>NCT03325790</nct_id>
  </id_info>
  <brief_title>SPI-1005 for the Treatment of Patients With Meniere's Disease</brief_title>
  <official_title>A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Efficacy of SPI-1005 in Meniere's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sound Pharmaceuticals, Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sound Pharmaceuticals, Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, efficacy, and Pharmacokinetics (PK) of two dose levels
      of SPI-1005 administered for 28 days compared to placebo in patients with Meniere's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study participants will be randomized to SPI-1005 or placebo in this double-blind study to
      evaluate both safety and efficacy of the investigational treatment. Participants, aged 18-75
      years, with probable or definite Meniere's disease will undergo baseline testing to assess
      severity of sensorineural hearing loss, tinnitus and vertigo. During the study, and 28 days
      after completion of treatment, participants will be evaluated for safety (adverse events,
      physical examinations, vital signs and clinical laboratory testing (CBC,serum chemistry).
      Trough plasma levels of ebselen and its major metabolite will be determined using liquid
      chromatography-mass spectrometry (LCMS) at specified visits. Additionally, plasma will be
      analyzed for selenium at the corresponding visits. The effect of SPI-1005 on hearing and
      balance will be evaluated. Tinnitus (TFI) and vertigo (VSS) will be evaluated at baseline,
      during and study treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2017</start_date>
  <completion_date type="Actual">April 30, 2019</completion_date>
  <primary_completion_date type="Actual">April 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>DOUBLE-BLIND</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of SPI-1005 treatment in adults with Meniere's disease</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number and severity of adverse events in patients treated with placebo versus SPI-1005</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of SPI-1005 on hearing loss</measure>
    <time_frame>12 weeks</time_frame>
    <description>Improvement in sensorineural hearing loss from baseline using Pure Tone Audiometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of SPI-1005 on word recognition score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Improvement in word recognition score from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of SPI-1005 on tinnitus</measure>
    <time_frame>12 weeks</time_frame>
    <description>Improvement in the Tinnitus Functional Index from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of SPI-1005 on tinnitus loudness</measure>
    <time_frame>12 weeks</time_frame>
    <description>Improvement in Tinnitus Loudness on response to Tinnitus Functional Index Question Number 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of SPI-1005 on vertigo</measure>
    <time_frame>12 weeks</time_frame>
    <description>Improvement in Vertigo Symptom Scale from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration of SPI-1005</measure>
    <time_frame>12 weeks</time_frame>
    <description>Maximum plasma concentration of SPI-1005 will be determined at certain time intervals</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Meniere's Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200mg SPI-1005 twice daily (BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg SPI-1005 BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400mg SPI-1005 BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400mg SPI-1005 BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>200mg SPI-1005 BID</intervention_name>
    <description>Active: low dose</description>
    <arm_group_label>200mg SPI-1005 twice daily (BID)</arm_group_label>
    <other_name>ebselen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>400mg SPI-1005 BID</intervention_name>
    <description>Active: high dose</description>
    <arm_group_label>400mg SPI-1005 BID</arm_group_label>
    <other_name>ebselen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male and female patients, 18-75 years of age at the time of enrollment.

          -  Diagnosis of probable or definitive Meniere's disease by American Academy of
             Otolaryngology-Head and Neck Surgery (AAO-HNS) 1995 criteria.

          -  Two of three active symptoms including vertigo or disequilibrium, fluctuating hearing
             loss, or tinnitus within the 3 months prior to study enrollment.

          -  Hearing loss of â‰¥ 30 decibels (dBHL) at either 250, 500 or 1000 Hz.

          -  Voluntary consent to participate in the study.

          -  Male subjects that are willing to use condoms throughout the study period and 90-days
             following study completion even if not fertile.

          -  Females of childbearing potential should either be sexually inactive (abstinent) for
             14 days prior to screening and throughout the study or be using one of the following
             acceptable birth control methods:

               -  Intrauterine Device in place for at least 3 months prior to study; or

               -  Barrier method (condom or diaphragm) with spermicide for at least 14 days prior
                  to screening through study completion; or

               -  Stable hormonal contraceptive for at least 3 months prior to study and through
                  study completion; or

               -  Surgical sterilization (vasectomy) of partner at least 6 months prior to study
                  enrollment.

          -  Females of non-childbearing potential should be surgically sterile (bilateral tubal
             ligation with surgery at least 6 months prior to study enrollment, hysterectomy, or
             bilateral oophorectomy at least 2 months prior to study) or be at least 1 year since
             last menses.

        Exclusion Criteria:

          -  Current use of or within 60 days prior to study IV ototoxic medications such as
             chemotherapy including cisplatin, carboplatinum, or oxaliplatin; aminoglycoside
             antibiotics including gentamicin, amikacin, tobramycin, kanamycin, or streptomycin; or
             loop diuretics including furosemide.

          -  History of otosclerosis or vestibular schwannoma.

          -  History of significant middle ear or inner ear surgery.

          -  Current conductive hearing loss, otitis media, or mixed hearing loss.

          -  Significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal,
             endocrine, immunologic, or psychiatric disease.

          -  Current use or within 30 days prior to study enrollment systemic steroids or drugs
             known to be strong inhibitors or inducers of cytochrome P450 enzymes.

          -  Hypersensitivity or idiosyncratic reaction to compounds related to ebselen or
             selenium.

          -  Female patients who are pregnant or breastfeeding.

          -  Participation in another interventional drug or device study within 30 days prior to
             study consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Kil, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sound Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ccent/Cccr</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMiami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KUMC</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced ENT &amp; Allergy</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENT and Allergy Associates, LLP</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEENTA</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TJU</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUSC</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Ear, Inc.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.soundpharma.com</url>
    <description>Sound Pharmaceuticals, Inc.</description>
  </link>
  <reference>
    <citation>Kil J, Pierce C, Tran H, Gu R, Lynch ED. Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hear Res. 2007 Apr;226(1-2):44-51. Epub 2006 Oct 6.</citation>
    <PMID>17030476</PMID>
  </reference>
  <reference>
    <citation>Lynch E, Kil J. Development of ebselen, a glutathione peroxidase mimic, for the prevention and treatment of noise-induced hearing loss. Semin Hear 2009; 30(1):47-55</citation>
  </reference>
  <reference>
    <citation>Kil J, Lobarinas E, Spankovich C, Griffiths SK, Antonelli PJ, Lynch ED, Le Prell CG. Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2017 Sep 2;390(10098):969-979. doi: 10.1016/S0140-6736(17)31791-9. Epub 2017 Jul 14.</citation>
    <PMID>28716314</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>October 4, 2017</study_first_submitted>
  <study_first_submitted_qc>October 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2017</study_first_posted>
  <last_update_submitted>June 14, 2019</last_update_submitted>
  <last_update_submitted_qc>June 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meniere's disease</keyword>
  <keyword>Hearing Loss</keyword>
  <keyword>Vertigo</keyword>
  <keyword>Tinnitus</keyword>
  <keyword>Ebselen</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Speech</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meniere Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ebselen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

